10x Genomics (TXG) Rides Slide DNA Optimism, Is The Stock Fully Priced?

Recent sector optimism around slide-DNA sequencing for copy number mapping has put fresh attention on 10x Genomics (TXG), as investors weigh how genomic research and precision medicine trends intersect with the company’s single-cell and spatial biology tools.

Recent enthusiasm around slide-DNA sequencing has collided with a sharp pullback in 10x Genomics’ share price. The stock fell 14.04% on a 1-day basis and is down 22.42% over 30 days, even after a 90-day share price return of 48.30% and a year-to-date share price gain of 321.78% that aligns with a very strong 1-year total shareholder return of 413.93%. Longer term holders are still facing a 5-year total shareholder loss of 60.61%, despite a 3-year total shareholder gain of 76.49%, as sentiment resets around how much of the sector optimism is already reflected in the current US$70.10 level.

Scan beyond 10x Genomics and compare it with hand-picked genomic and precision medicine peers using our 34 healthcare AI stocks built around healthcare AI driven research tools.

After a sharp reset in 10x Genomics’ share price and a cluster of fair value estimates around the current US$70.10 level, the key question is how much upside or downside that spread actually implies.

Most Popular Narrative: 9.5% Undervalued

On the most followed view, 10x Genomics screens about 9.5% below an implied fair value of $77.50, using an 8.03% discount rate and analyst style assumptions about future revenue, profitability and AI related use cases.

Recent and upcoming product launches, including Flex v2 (targeting higher throughput, lower costs, and AI integration), Visium HD extensions, and Xenium RNA plus protein, are expanding the range of applications and reinforcing 10x''s leadership in advanced genomics tools, expected to drive both top-line growth and sustain premium pricing over time.

See why 28 investors see 10x Genomics as 10% undervalued.

Result: Fair Value of $77.50 (UNDERVALUED)

Still, academic funding pressure and ongoing operating losses at 10x Genomics could blunt demand for new platforms and prolong the path to consistent profitability.

Find out about the key risks to this 10x Genomics narrative.

Another View: What 10x Genomics’ P/S Ratio Signals

That 9.5% gap to an implied fair value of $77.50 is based on analyst forecasts and discount rates. A simple P/S check tells a tougher story. 10x Genomics trades at about 14.8x sales compared with roughly 5x for both peers and a fair ratio of about 7x, which points to meaningful valuation risk if sentiment cools.

For a clearer view of what this kind of pricing gap can mean for future returns, see what the numbers indicate about this price in our valuation breakdown, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on 10x Genomics so far. If you want a clear opinion grounded in the actual data, move quickly and weigh up both sides by checking the 1 key reward and 3 important warning signs.

Looking for more 10x Genomics style investment ideas?

If 10x Genomics has sharpened your appetite for focused research, do not stop here. Fresh ideas across sectors can sharpen your portfolio decisions even further.

• Target potential bargains with resilient fundamentals by scanning a curated set of quality candidates using the 29 high quality undervalued stocks.
• Strengthen your income playbook by zeroing in on companies that pair substantial yields with staying power through the 5 dividend fortresses.
• Dial down portfolio risk by filtering for sturdier balance sheets and steadier profiles using the 30 resilient stocks with low risk scores.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com